Forecasted · Cooperative Agreement
NIH Blueprint Initiative: Tools for Germline Gene Editing in the Nervous System
National Institutes of Health, Department of Health and Human Services
Key facts
Copied from the official Grants.gov record. Last verified October 29, 2026.
- Program name
- NIH Blueprint Initiative: Tools for Germline Gene Editing in the Nervous System
- Issuing agency
- National Institutes of Health (Department of Health and Human Services)
- Opportunity number
- RFA-DA-27-012
- Funding type
- Cooperative Agreement
- Funding purpose
- Health
- Status
- Forecasted
- Application deadline
- Forecasted · estimated close October 12, 2026 (agency estimate)
- Agency estimates
- Estimated posting: August 10, 2026. Estimated award date: July 1, 2027. Estimates can change.
- Published award range
- Up to $1,200,000
- Estimated total program funding
- $7,200,000
- Expected number of awards
- 4
- Cost sharing or match required
- No
- Eligible applicants (official categories)
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see Additional Information on Eligibility)
- Relevant to
- Businesses and NonprofitsHow we determined this: Grants.gov eligibility includes small businesses or for-profit organizations. Grants.gov eligibility includes nonprofit organizations.
- Geographic restrictions
- None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.
- Assistance Listing (CFDA)
- 93.279
- Official source
- View on Grants.gov ↗
- Application URL
- www.grants.gov/search-results-detail/362313 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.
- Source identifier
- Grants.gov opportunity ID 362313 · Funding opportunity number RFA-DA-27-012
- Posted
- May 7, 2026 · Source last updated May 7, 2026
- Last verified
- October 29, 2026 (against Grants.gov)
- Data completeness
- 100% of key fields published by the source
- Record confidence
- mediumforecast — dates and amounts are agency estimates.
Eligibility details (from the agency)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Description (from the official listing)
The NIH Blueprint (a consortium of NIH Institutes that support neuroscience research) seeks to advance its mission by supporting the development, optimization, validation, and application of germline and somatic transgenic and gene-editing approaches in experimental systems modeling key features of human brain anatomy, circuitry, cognition, behavior, and lifespan. This initiative will build on the previously supported marmoset gene-editing infrastructure, by integrating New Approach Methodologies (NAMs) with other models, to advance understanding of human brain function and disease, including human-derived NAMs for cross-species comparisons across development. Many mechanisms of complex conditions, such as autism spectrum disorders, schizophrenia, and other behavioral/developmental disorders, cannot yet be captured in NAMs and are therefore high priorities for research investment to accelerate development and validation of human-derived NAMs. Appropriate models should be used and clearly justified as necessary for questions involving neuroanatomy, circuit function, cognition, behavior, or lifespan phenotyping related to human brain disease and function. Grant authorities are as follows: 42 U.S.C 241 and 284.
Agency contact
NIDA GED Program Staff
NIDA_GED_Program@nida.nih.gov